VISEN Discloses 52-week Clinical Results for Its China Phase 3 Trial of Lonapegsomatropin
Currently the Only Long-Acting Growth Hormone Demonstrates Superior Annualized Height Velocity Compared to Daily hGH in Children with Growth Hormo...
Source: businessinsider.com